539470
Proteinase K Inhibitor
Proteinase K Inhibitor is a tetrapeptidyl chloromethyl ketone compound that acts as an active-site-targeting irreversible inhibitor against proteinase K.
Synonym(s):
Proteinase K Inhibitor, MeOSuc-AAPF-CMK
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
Assay
≥97% (HPLC)
form
lyophilized
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated
protect from light
solubility
DMSO: 3 mg/mL
shipped in
ambient
storage temp.
−20°C
General description
A tetrapeptidyl chloromethyl ketone compound that acts as an active-site-targeting irreversible inhibitor against proteinase K (Cat. Nos. 539480, 70663, & 71049). Shown to be more potent than MeOSuc-AAPV-CMK (Cat. Nos. 324745) in preventing the degradation of reverse transcriptase and albumin by proteinase K.
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Sequence
MeOSuc-Ala-Ala-Pro-Phe-CH₂Cl
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at -20°C.
Other Notes
Kore, A.R., et al. 2009. Bioorg. Med. Chem. Lett.19, 1296.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nature communications, 12(1), 6726-6726 (2021-11-20)
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform CODEX multiplexed tissue
Nature communications, 13(1), 1606-1606 (2022-03-27)
The cellular processes that govern tumor resistance to immunotherapy remain poorly understood. To gain insight into these processes, here we perform a genome-scale CRISPR activation screen for genes that enable human melanoma cells to evade cytotoxic T cell killing. Overexpression
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service